Clinical Trial Update: Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating alirocumab added to rosuvastatin versus other lipid-modifying treatments in hypercholesterolemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Rosuvastatin (rosuvastatin)
• alirocumab (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2015-10-28